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Abstract 
Mixed cryoglobulinaemia vasculitis (CryoVas) is a small-vessel systemic vasculitis caused by 
deposition of mixed cryoglobulins and is characterized by a wide range of clinical symptoms. 
HCV is the primary cause of CryoVas, which is associated with significant morbidity and 
mortality. The mortality rate among patients with HCV-associated CryoVas is 3× that of the 
general population, with a 63% 10-year survival rate. First-line treatment for CryoVas is anti-
HCV therapy because viral clearance is associated with clinical improvement. The 
introduction of highly effective, interferon-free, direct-acting antiviral regimens provides 
additional treatment options for these patients. Here, we review recent studies investigating 
the effect of antiviral therapy on HCV-associated CryoVas and provide expert opinion for 
health-care professionals managing these patients. 
Introduction 
Mixed cryoglobulinaemia vasculitis (CryoVas) is a small-vessel systemic vasculitis caused by 
deposition of circulating immunoglobulins (Igs) called mixed cryoglobulins. Mixed 
cryoglobulins consist of polyclonal IgG and either monoclonal or polyclonal IgM with 
rheumatoid factor activity. CryoVas affects different organs and disease expression can range 
from mild clinical symptoms to life-threatening complications [1]. Patients exhibiting clinical 
symptoms associated with the disease should be considered for a diagnosis of CryoVas, which 
is confirmed by testing for Igs that precipitate from serum when it is cooled to below core 
body temperature and resolubilize when the serum is rewarmed [1]. 
Infection with HCV has been identified as the main cause for CryoVas. HCV plays a primary 
role in the development of the immune complexes that initiate tissue damage, and over 90% 
of patients with CryoVas were infected with HCV [2–4]. Due to the causative association, 
testing for HCV in patients with CryoVas is necessary, and screening for CryoVas in HCV-
infected patients with signs and symptoms of CryoVas is an important consideration in 
managing the disease. 
Why should we treat HCV-infected patients 
suffering from CryoVas? 
HCV infection is highly prevalent in patients with CryoVas and mixed cryoglobulins are 
present in 25–45% of patients with HCV [4,5]. A minority of patients with HCV and mixed 
cryoglobulins exhibit symptomatic CryoVas, which is present in approximately 10–35% of 
patients who are HCV-positive and cryoglobulin-positive [4,5]. CryoVas has a variety of 
clinical features, which range from rare to highly prevalent, affecting mainly the skin, joints, 
peripheral nervous system and kidneys (Table 1). Symptoms are often initially mild, with 
fatigue, palpable purpura and arthralgia as the most common symptoms [6]. The disease may 
progress to more severe symptoms, including life-threatening widespread vasculitis with 
glomerulonephritis, or central nervous system, heart or gut involvement. The skin is where 
symptoms are most frequently exhibited, usually as purpura, though chronic cutaneous ulcers 
may follow [7]. The purpura begins in the lower limbs, with spread to the lower abdominal 
area, trunk and upper limbs occurring less frequently [1,7]. Joint pain is typically bilateral and 
symmetric, involving knees and hands [1]. A range of neurological manifestations can result, 
but the most frequently described neurological manifestation is a distal sensory or sensory–
motor polyneuropathy, usually presenting as a painful, asymmetric paraesthesia, later 
becoming symmetric [7]. Renal involvement occurs in approximately 30% of patients, most 

















Table 1. Clinical features of mixed cryoglobulinaemia vasculitis associated with HCV 
infection [6]  






Peripheral neuropathy 81 
Liver involvement 73 
Sicca syndrome 51 
Raynaud’s phenomenon 32 
Renal involvement 31 
B-cell NHL 11 
Arthritis (non-erosive) 8 
Hepatocellular carcinoma 3 
 
Reprinted with permission from Hepatitis C virus syndrome: a constellation of organ- and 
non-organ specific autoimmune disorders, B-cell non-hodgkin’s lymphoma, and cancer by 
Ferri C, Sebastiani M, Giuggioli D, et al. (2015) in World J Hepatol 7:327–343. 
a
Prevalence 
calculated in 100 consecutive, unselected Italian patients with mixed cryoglobulinaemia (92% 
had chronic HCV infection) evaluated at the end of follow-up. NHL, non-Hodgkin 
lymphoma. 
 
HCV-associated CryoVas is linked to significant morbidity and mortality [1,8]. In a study of 
151 consecutive French patients with HCV-associated vasculitis, patients had a poor long-
term prognosis (Figure 1). There were 32 deaths, which were predominately due to serious 
infection and/or end-stage liver disease, and the observed death rate was nearly 3× that of the 
expected mortality rate compared with age- and sex-matched individuals from the overall 
French population (standardized mortality ratio 2.7; 95% CI 1.8, 3.9) [8]. Among HCV-
infected patients with CryoVas, the 1-year survival rate was 96%, the 3-year rate was 86%, 
the 5-year rate was 75% and the 10-year rate was 63% [8]. In multivariate analysis, severe 
fibrosis (hazard ratio [HR] 10.8, 95% CI 3.6, 32.1; P<0.0001) and the Five-Factors Score 
(FFS) vasculitis scoring system (HR 2.5, 95% CI 1.3, 4.8; P=0.007) were significantly 
associated with mortality [8]. The FFS ranges from 1 to 5 with points assigned for the 
presence of proteinuria (1 g/day), renal insufficiency (serum creatinine level >140 μmol/l), 








Figure 1. Kaplan–Meier estimates of survival for 151 patients with HCV-related vasculitis [8]  
Reprinted with permission from Prognostic factors in patients with hepatitis C virus infection 
and systemic vasculitis by Terrier B, Semoun O, Saadoun D et al. (2011) in Arthritis Rheum 
63:1748–1757. Patients were followed prospectively between 1993 and 2009 (median 54 
months’ follow-up). 
Cryoglobulinaemia is correlated with longer duration of HCV infection and older age. 
However, cryoglobulinaemia is associated with advanced fibrosis/cirrhosis in patients with 
chronic HCV infection, regardless of age or disease duration [9–11]. 
A 15-year prospective cohort study of HCV-infected patients with either symptomatic 
CryoVas or no circulating cryoglobulins assessed overall survival, progression of liver disease 
and cryoglobulin-related complications in these patients [12]. The 15-year cumulative 
probability of renal insufficiency was significantly greater in HCV-infected patients with 
CryoVas than in those without CryoVas (33% versus 3%, respectively; P<0.0001) [12]. 
Patients with cryoglobulinaemic syndrome also had increased cumulative incidence of 
neurological impairment (31% versus 5%; P<0.0001) and B-cell non-Hodgkin lymphoma 
(15% versus 7%; P=0.003) [12]. In contrast, patients without CryoVas had a higher 
cumulative incidence of cirrhosis or hepatocellular carcinoma (25% versus 14%, P<0.005; 
20% versus 8%, P=0.003, respectively) [12]. The 15-year survival rate was not significantly 
different between the two groups (70% versus 72%), but patients in both groups who received 
antiviral therapy lived significantly longer than those who did not receive antiviral therapy 
[12]. An analysis of 231 Italian patients with CryoVas found a significantly lower survival 
rate in CryoVas patients (92% HCV-infected) compared with the expected survival of age- 
and sex-matched patients in the general population. Furthermore, CryoVas patients with renal 
involvement had increased risk of mortality (HR=2.97; P<0.0001) [13]. 
Though it is a less common clinical feature, CryoVas patients have an increased risk for the 
development of B-cell non-Hodgkin lymphoma [6]. In a retrospective study of 1,255 HCV-
positive Italian patients with cryoglobulinaemic syndrome, patients were followed 
cumulatively for 8,928 patient-years [14]. Overall, 59 patients developed B-cell non-Hodgkin 
lymphoma, resulting in an incidence rate that was 35× higher in cryoglobulinaemic syndrome 
patients than in the general population (6.6 versus 0.2 cases, respectively, per 1,000 patients) 
[14]. There were 20 cases of aggressive B-cell non-Hodgkin lymphoma in cryoglobulinaemic 
syndrome patients (2.2 cases per 1,000 patients), which was 12× greater than in the general 
population [14]. 
How do we diagnose and treat HCV-
infected patients with CryoVas? 
Diagnosis 
It is important that clinicians are able to recognize HCV-associated CryoVas and other 
extrahepatic manifestations of chronic HCV infection so that patients can receive timely 
diagnosis and treatment [15]. A diagnosis of CryoVas should be considered in patients who 
exhibit clinical features of the condition (Table 1), and further confirmed by the detection of 
cryoglobulins in the patient’s serum [1]. Cryoglobulins are detected by precipitation from a 
patient’s serum after it is cooled to 4°C for 7 days and resolubilization when the patient’s 
serum is warmed back to 37°C [1]. Following detection of cryoglobulins, they are 
immunochemically categorized into three types: type I, consisting of monoclonal Igs; type II, 
consisting of a polyclonal IgG bound to a monoclonal IgM with rheumatoid factor activity; 
and type III, consisting of a polyclonal IgG bound to a polyclonal IgM with rheumatoid factor 
activity [1,7,16]. Type II and III cryoglobulins are referred to as mixed cryoglobulins, and 70–
90% of patients with mixed cryoglobulinaemia have HCV infection [1]. Type I cryoglobulins 
are highly associated with B-cell lymphoproliferative disease, which can present as either 
haematological malignancy or a benign B-cell proliferation [1,7]. There are other laboratory 
tests that provide indirect evidence of cryoglobulinaemia and use markers that are easier to 
detect than cryoglobulins. These tests include low C4 serum complement fraction, decreased 
total haemolytic complement levels and presence of rheumatoid factor activity [1]. 
Diagnostic guidelines proposed by the International Study Group of Extrahepatic 
Manifestations Related to Hepatitis C Infection (ISG-EHCV) note that because serum mixed 
cryoglobulin levels may vary between patients, and in a single patient, over the course of the 
disease, patients with suspected CryoVas may require repeat screenings to avoid a false-
negative error [15]. The guidelines also note that low C4 serum level may be a useful 
screening test [15]. Symptoms of CryoVas may also vary between patients and over the 
course of the disease, leading to difficulty in differentiating CryoVas from other diseases with 
overlapping symptoms. Guidelines issued by the ISG-EHCV, suggest using the presence of 
purpura, weakness, renal involvement, peripheral neuropathy and laboratory alterations in 
mixed cryoglobulins, low C4 and rheumatoid factor as parameters to differentiate a diagnosis 
of CryoVas from sicca syndrome, Sjögren’s syndrome or rheumatoid arthritis [15]. Given that 
a relatively small proportion of HCV-infected patients with circulating cryoglobulins exhibit 
symptoms [4], testing for circulating cryoglobulins, complement, serum creatinine, 
rheumatoid factor and urinalysis upon initial clinical evaluation would improve the diagnosis 
rate [17]. However, given current goals to expand treatment availability, careful consideration 
must be given to the resources required to screen asymptomatic patients who are likely to be 
treated with a highly effective direct-acting antiviral (DAA) regimen. 
Treatment 
Consistent with international guidelines on the treatment of chronic HCV, including both 
European Association for the Study of the Liver (EASL) and American Association for the 
Study of Liver Diseases (AASLD) treatment guidelines, treatment should be initiated without 
delay for patients with clinically significant extrahepatic manifestations of chronic HCV, 
including symptomatic CryoVas [18–20]. Indeed, patients with HCV-related vasculitis were 
rated as the highest-priority patients to treat among patients with extrahepatic manifestations 
[18]. Management of patients with HCV-associated CryoVas should be individualized 
according to the severity of CryoVas disease [1,21]. A proposed treatment algorithm for 
HCV-associated CryoVas is shown in Figure 2. Patients with mild-to-moderate CryoVas 
should be treated with an optimized interferon-free antiviral regimen. In severe cases, 
rituximab should be administered, with plasmapheresis if necessary, associated with 
interferon-free antiviral therapy [1]. There are limited treatment options beyond the treatments 
previously mentioned. Corticosteroids may be used to help control minor inflammatory 




Figure 2. Proposed treatment algorithm for HCV-associated mixed cryoglobulinaemia 
vasculitis [1]  
 
Reprinted with permission from Cryoglobulinemia vasculitis by Cacoub P, Comarmond C, 
Domont F, et al. (2015) in Am J Med 128:950–955. CNS, central nervous system; GN, 
glomerulonephritis; IV, intravenous. 
 
 
Impact of treatment 
CryoVas generally responds to clearance of HCV, as measured by achievement of a sustained 
virological response (SVR) [1,21]. A large cohort study of HCV-infected veterans in the 
United States (n=160,875) found that viral clearance with interferon-based therapy (with or 
without ribavirin) significantly reduced the risk of CryoVas [23]. Patients who achieved SVR 
were less likely to develop CryoVas than those who did not receive treatment (adjusted HR 
0.61, 95% CI 0.39, 0.94; P=0.0264) and those who received treatment but did not achieve 
SVR (adjusted HR 0.55, 95% CI 0.33, 0.90; P=0.0170) [23]. Initial studies with first-
generation DAAs (for example, telaprevir or boceprevir) with pegylated interferon and 
ribavirin showed interesting results, although concerns about safety limited their use [24]. In a 
prospective, controlled cohort study of HCV-infected patients with or without CryoVas 
treated with pegylated interferon and ribavirin, the rate of SVR 24 weeks after the end of 
treatment (SVR24) was 61% among patients without CryoVas and was significantly lower in 
patients with CryoVas, at 49% (P=0.014) [25]. Despite suboptimal efficacy, the majority 
(57% [36/63]) of patients with HCV-associated CryoVas who achieved an SVR24 had a 
complete clinical response (an improvement in all baseline clinical manifestations of 
CryoVas), whereas most others (40% [25/63]) had a partial clinical response (an improvement 
in at least half of the baseline clinical manifestations of CryoVas) at the end of long-term 
follow-up (mean follow-up of 92.5 months) [25]. A further open-label prospective cohort 
study evaluated the efficacy of pegylated interferon-α with ribavirin and a protease inhibitor 
(telaprevir or boceprevir) in HCV-infected patients with CryoVas [26]. Again, the SVR24 rate 
was suboptimal at 70% (16/23), but all patients had a clinical response of CryoVas, either 
complete (57% [13/23]) or partial (43% [10/23]) [26]. Discontinuation of antiviral therapy 
was required in 35% (8/23) of patients, and addition of the protease inhibitor to the regimen 
was associated with increased rates of anaemia, fatigue and infections compared with a 
similar study of pegylated interferon-α with ribavirin alone [26,27]. Furthermore, in a cohort 
of patients with severe liver disease, treatment with interferon-based triple therapy using a 
first-generation protease inhibitor was less effective in patients with CryoVas than in patients 
without CryoVas [28]. The introduction of interferon-free, DAA-based combinations has 
improved treatment efficacy, resulting in SVR rates greater than 90% and a very good safety 
profile, including in patients previously considered difficult to treat [24]. Studies of patients 
with HCV-associated CryoVas treated with DAAs have shown that CryoVas clinical response 
is also associated with SVR (Table 2). In the first prospective, open-labelled 
VASCUVALDIC study of 24 patients treated with sofosbuvir and ribavirin for 24 weeks, 
74% (17/23) achieved SVR 12 weeks after the end of treatment (SVR12), whereas a complete 
clinical response was achieved by most patients (87% [20/23]) at 12 weeks post treatment 
[29]. Notably, purpura, skin ulcers and arthralgia disappeared in all cases, whereas renal 
involvement improved in four out of five cases [29]. Currently, sofosbuvir plus ribavirin is 
not widely used due to lower SVR rates compared with combination DAA therapies. In a 
prospective study of guideline-tailored, sofosbuvir-based DAA therapy (sofosbuvir plus 
ribavirin, or sofosbuvir plus simeprevir, daclatasvir or ledipasvir, with or without ribavirin) in 
44 patients with HCV-associated CryoVas, all patients achieved SVR12 and SVR24 [30]. At 
the SVR24 time point, all patients had a CryoVas clinical response; 36% were full-complete 
responders (cleared all clinical manifestations of CryoVas), 41% were complete responders 
and 23% were partial responders [30]. In an open-label, prospective, multicentre study of 41 
French patients with HCV-associated CryoVas treated with sofosbuvir plus daclatasvir for 12 
or 24 weeks, all patients achieved SVR12 [31]. At week 24 of the study (SVR12 or end of 
treatment, depending on assigned treatment duration), 90% of patients had complete clinical 
response and 10% had partial clinical response [31]. Of note, this study also showed that 
DAA-based therapy restored disturbances in peripheral B- and T-cell homeostasis [32]. A 
Spanish prospective study evaluated 64 HCV-infected patients with circulating cryoglobulins 
(either with CryoVas [n=35] or asymptomatic circulating cryoglobulins [n=29]) who received 
therapy with a DAA-containing regimen [33]. In the overall population, 94% (60/64) of 
patients achieved SVR12, and among patients with symptomatic CryoVas, 71% (25/35) 
achieved complete clinical response and 14% (5/35) had partial response [33]. A similarly 
high SVR rate was observed in a real-world, retrospective chart review of CryoVas patients 
treated with DAA-based regimens in the HCV-TARGET database [34]. The SVR rate in 
CryoVas patients was 92% (54/59), and among the 27 SVR patients with sufficient follow-up 
information, 19 (61%) had resolution of CryoVas symptoms [34]. In a retrospective case 
series of 12 HCV-infected patients with CryoVas who were treated with sofosbuvir-based 
regimens, the 83% (10/12) SVR12 rate was higher than the historical control group of 
CryoVas patients treated with pegylated interferon plus ribavirin (10% [1/10]) [35]. In the 
sofosbuvir-based treatment cohort, patients with evidence of renal involvement who achieved 
SVR12 had improvement in serum creatinine and reduction in proteinuria [35]. High SVR 
rates and a strong correlation between virological and clinical response were observed in a 
study using, in most cases (11 out of 17 patients), non-sofosbuvir-based therapy 
(paritaprevir/ritonavir, ombitasvir and dasabuvir, with or without ribavirin) [36]. 
 
Table 2. Outcomes of cryoglobulinaemia in patients with chronic hepatitis C treated with 




Defined as improvement in all affected organs and the absence of clinical relapse. 
b 
36% of 
patients had a full-complete response (cleared all clinical manifestations of cryoglobulinaemia 
vasculitis [CryoVas]), 41% had a complete response (improvement in all clinical 
manifestations), 23% had partial improvement. 
c 
Birmingham Vasculitis Activity Score =0, or 
all affected organs improved. 
d 
Resolution of all manifestations. DAA, direct-acting antiviral; 
DAC, daclatasvir; LDV, ledipasvir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR, 
sustained virological response. 
In addition to eradication of HCV with interferon- or DAA-based therapies, immunotherapy 
with rituximab has also been shown to significantly reduce vasculitis disease activity in 
patients with severe CryoVas. Rituximab is a chimeric monoclonal antibody that binds to the 
CD20 antigen, a transmembrane protein selectively expressed on pre-B and mature 
lymphocytes [4]. CD20-positive cells are expanded and activated in CryoVas patients [37,38]. 
In a randomized controlled trial of rituximab versus conventional treatment (glucocorticoids, 
azathioprine or cyclophosphamide, or plasmapheresis) in 59 patients with severe CryoVas, 
only treatment with rituximab was shown to significantly reduce the mean Birmingham 
Vasculitis Activity Score (BVAS) from baseline (11.9 ±5.4 [standard deviation (SD)]) up to 
month 24 (4.4 ±4.6 [SD]; P<0.0001) [39]. The BVAS ranges from 0 (remission) to 68 and 
includes scores assigned for general symptoms (arthralgia, arthritis and fever) and major 
organ involvement (skin, mucous membranes, ear/nose/throat, cardiovascular, pulmonary, 
gastrointestinal, renal, nervous system). Persistent symptoms or manifestations at each site are 
assigned 1 point and new or worsening symptoms are assigned 2 points [36]. In this study, 
93% (53/57) of patients were infected with HCV but were ineligible for antiviral therapy due 
to prior treatment failure or because treatment was contraindicated. Other studies have shown 
that rituximab improves patient outcomes when combined with antiviral treatment. A 
prospective cohort study of patients with HCV-associated CryoVas treated with pegylated 
interferon-α plus ribavirin found that patients who received rituximab prior to antiviral 
therapy had a shorter time to clinical remission (5.4 ±4.0 [SD] months versus 8.4 ±4.7 [SD] 
months in patients who did and did not receive rituximab, respectively; P=0.004) and had 
better renal response rates (81% versus 40% complete response; P=0.04) [27]. In a similar 
prospective, single-centre, randomized study of pegylated interferon-α plus ribavirin with or 
without rituximab, 55% (12/22) of patients who received rituximab achieved complete 
response, compared with 33% (5/15) of patients who received pegylated interferon-α plus 
ribavirin alone (P<0.05) [40]. The use of rituximab in CryoVas patients with advanced liver 
disease was not only safe but also associated with a consistent clinical improvement in hepatic 
function in patients with decompensated cirrhosis [41]. 
Challenges in managing HCV and CryoVas 
A significant challenge in treating patients with CryoVas is curing HCV infection in those 
with severe renal impairment (glomerular filtration rate <30 ml/min/1.73 m
2 
) or end-stage 
renal disease (ESRD) requiring dialysis [42]. The safety of sofosbuvir-based regimens has not 
been assessed in patients with severe renal impairment or ESRD, and these regimens are not 
indicated for treatment in these patients [43–46]. EASL and AASLD guidelines do not 
recommend sofosbuvir-containing regimens for patients with severe renal impairment or 
ESRD; the guidelines do recommend the cautious use of ribavirin only at a reduced dose and 
with haematopoietic monitoring [19,20]. For HCV GT1-infected patients, EASL guidelines 
recommend the combination of ritonavir-boosted paritaprevir, ombitasvir and dasabuvir or the 
combination of grazoprevir and elbasvir (both regimens without ribavirin for GT1b and with 
reduced-dose ribavirin for GT1a) [20]. For HCV GT4-infected patients, EASL guidelines 
recommend the combination of ritonavir-boosted paritaprevir and ombitasvir with reduced-
dose ribavirin or the combination of grazoprevir and elbasvir without ribavirin [20]. For 
patients infected with HCV GT2 or GT3 who are in urgent need of treatment, EASL 
guidelines recommend the combination of sofosbuvir and velpatasvir or sofosbuvir and 
daclatasvir for GT2-infected patients and sofosbuvir and velpatasvir without ribavirin or 
sofosbuvir and daclatasvir with ribavirin for GT3-infected patients; renal function should be 
monitored in these patients and treatment interrupted immediately in the case of deterioration 
[20]. 
Several regimens have pangenotypic anti-HCV activity including the combination of 
sofosbuvir plus daclatasvir, which must be prescribed separately, and three fixed-dose 
combination regimens (sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir and 
glecaprevir/pibrentasvir). The latter two were recently approved in both the European Union 
and the United States [46–49]. It should be noted that sofosbuvir/velpatasvir/voxilaprevir is 
approved for both treatment-naive and -experienced patients in the EU, whereas in the United 
States it is approved only as a salvage regimen for patients who have not responded to other 
DAA-containing regimens [46,47]. No dose adjustment of glecaprevir and pibrentasvir is 
required in patients with any degree of renal impairment, including those on dialysis [48,49], 
providing an additional option for CryoVas patients with severe renal impairment or ESRD. 
Moreover, the combination of glecaprevir and pibrentasvir has been evaluated in patients with 
HCV genotype 1–6 infection and CKD stage 4–5 disease [50]. The overall SVR rate was 
98%, which demonstrates that this combination has pangenotypic activity and is effective in 
patients with severe renal impairment. 
Additionally, as the introduction of highly effective HCV therapies has increased the pool of 
CryoVas patients who have eradicated HCV, a small but significant population of patients 
who have CryoVas or have persistence of circulating cryoglobulins without CryoVas despite 
being cured of HCV are being identified. Studies of HCV-infected patients treated with 
interferon-based regimens have shown that a minority of patients who achieved viral 
eradication did not have a complete recovery of CryoVas-related symptoms and experienced 
persistence or relapse of CryoVas [51,52]. In most patients, relapse occurred shortly after 
interferon-based antiviral treatment was stopped, and symptoms were less severe and short-
lived [52]. More recent clinical trials of DAA regimens have shown that persistence of 
CryoVas was rare after HCV clearance (0–3%) [25,30,31]. Available data suggest that the 
degree of reversibility of CryoVas is inversely correlated with the degree of 
lymphoproliferative disorder evolution and/or of organ damage, indicating that the eradication 
of HCV infection is needed as early as possible [53]. The long-term follow-up of such 
patients is mandatory, particularly to detect the appearance of non-Hodgkin lymphoma. Low- 
or medium-dose glucocorticoids, cyclophosphamide, mycophenolate mofetil, anti-CD20 
antibodies rituximab or ofatumumab, or anti-B-cell activating factor antibody belimumab are 
potential second-line therapies for patients who have cleared HCV but continue to show 
symptoms of CryoVas [4,54]. 
Unmet needs 
An unmet need in the treatment of HCV-associated CryoVas is patients receiving early 
treatment. Patients in the early stage of HCV infection exhibiting symptoms of CryoVas may 
be considered less urgent to treat, despite the association of HCV clearance and resolution of 
symptoms. A cohort study of veterans in the United States treated with interferon-based 
therapy found that the protective effect of SVR against certain extrahepatic manifestations, 
such as glomerulonephritis and non-Hodgkin lymphoma, was lessened as the time from HCV 
diagnosis to initiation of HCV therapy increased [20]. To ensure that all CryoVas patients are 
eligible for HCV therapy, treatment options that include interferon-free, and ideally ribavirin-
free, regimens are needed. Furthermore, it is important to ensure adequate follow-up for 
HCV-infected patients with CryoVas to rule out inadequate response or relapse. The long-
term follow-up of patients with HCV cure and positive circulating cryoglobulins is 
mandatory, considering the risk of developing non-Hodgkin lymphoma. 
Conclusions 
CryoVas is closely associated with HCV infection, and HCV eradication through antiviral 
therapy is the key therapeutic approach to be performed. Studies have shown that patients 
with HCV-associated CryoVas who achieved HCV eradication also achieved a complete or 
partial clinical reduction in CryoVas symptoms. The introduction of high-efficacy, interferon-
free DAA regimens have led to more treatment options and higher virological, clinical and 
immunological response rates and have expanded the pool of CryoVas patients able to be 
treated. Also, immunotherapy with first-generation anti-CD20 drugs (rituximab), or future 
second- or third-generation anti-CD20 drugs, in addition to antiviral therapy is an option for 
patients with severe CryoVas. Most HCV-infected patients with circulating cryoglobulins do 
not exhibit symptomatic disease, but the high correlation between HCV viral clearance and 
clinical response of CryoVas demonstrates the importance of the diagnosis and treatment of 
HCV-associated CryoVas. Patients with symptomatic disease that persists after antiviral 
therapy remain candidates for immunotherapy. As the pool of patients cleared of HCV with 
high-efficacy DAAs grows, the frequency of patients with persistence or relapse of CryoVas-
associated symptoms after viral eradication will need to be monitored and optimized 
treatment options assessed. 
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